Abstract
The economic literature reveals that the relationship between patents and Foreign Direct Investments (FDI) depends on industries and countries’ features. Our research considers the pharmaceutical industry in China. This choice stems from a contradictory observation: China is known for its important imitation capacities, but at the same time, it is becoming one of the most attractive destinations to technology intensive FDI, for instance, pharmaceutical FDI. To explore whether patent protection plays a role in attracting pharmaceutical FDI in China we conduct a documentary analysis over the 1980–2015 period. Data is compiled from specialized press and international and national economic institutions (such as the World Trade Organization-WTO and the Chinese Intellectual Property Office—SIPO). Using these statistics, we construct a composite index measuring the pharmaceutical patent protection in China (PPP index) to analyze its correlation with inward pharmaceutical FDI. For a better reliability of the results, the study considers only the forms of FDI that are—according to economic literature—the most sensitive to patent protection, i.e., drugs producing and/or research and development (R&D) FDI. Our analysis suggests that enhancing drug patent protection could have had a positive impact on inward pharmaceutical FDI in China, especially R&D subsidiaries. However, this impact is conditioned by the existence of other advantages for FDI location such as the development of technology parks and the knowledge-based human capital policy. Hence, drug patent protection would be a determinant for attracting pharmaceutical FDI provided that it is a part of a strong innovation system and active innovation policies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
Ownership, Location, Internalization.
References
Aho, E. (2013). Les déterminants des investissements directs étrangers dans la Communauté des Etats de l’Afrique de l’Ouest (CEDEAO), Revue d’Economie Théorique et Appliquée, Volume 3 – Numéro 2.
Bosworth, D., & Yang, D. (2000). Intellectual Property law, technology flow and licensing opportunities in China. International Business Review, 9(4), 453–477.
CEIC. (2017). China foreign direct investment. CEIC Institutional Investor Company. https://www.ceicdata.com/en/indicator/china/foreign-direct-investment
Combe, E., & Pfister, E. (2001). Le Renforcement International des Droits de Propriété Intellectuelle, Economie Internationale, La Revue du CEPII, N°85, Premier Trimestre 2001, pp 63–81.
Coriat, B., & Orsi, F. (2004). Les Enjeux de L’Innovation. Droits de Propriété Intellectuelle et Innovation. Cahiers Français, N°323, pp. 90–95.
Drug Patent Watch. (2017). Profile for patents. https://www.drugpatentwatch.com/
Fai, F. M. (2005). Using intellectual property data to analyze china’s growing technological capabilities. World Patent Information, 27, 49–61.
Ferrantino, M. J. (1993). The effect of intellectual property rights on international trade and investment. Weltwirtschaftliches Archiv, 129, 300–331.
Fink, C. (1997). Intellectual property rights and US and German international transactions in manufacturing industries. Duke Journal of Comparative and International Law, 9, 163.
Ginarte, J. C., & Park, W. G. (1997). Determinants of patent rights: A cross-national study. Research Policy, 26(3), 283–301.
Glass, A. J., & Saggi, K. (2002). Intellectual property rights and foreign direct investment. Journal of International Economics, 56, 387–410.
Hassan, E., Yaqub, O., & Diepeveen, S. (2010). Intellectual property and developing countries: A review of literature. RAND Corporation prepared for the UK Intellectual Property Office and the UK Department for International Development.
IHEST. (2015). « L’industrie pharmaceutique, l’innovation et la Chine ». Institut des Hautes Études pour la Sciences et la Technologie, Septembre 2015. http://www.ihest.fr/IMG/pdf/l_industrie_pharmaceutique_en_chine_maj_2015_final.pdf
IRACM. (2017). Définition de la falsification de médicaments. Institut International de Recherche Anti-contrefaçon des médicaments. http://www.iracm.com/falsification/definition/
Kirkilis, D., & Koboti, S. (2015). Intellectual property rights as determinant of foreign direct investment entry mode: The case of Greece. Procedia Economics and Finance, 19, 3–16.
Kumar, N. (2000). Explaining the geography and depth of international production: The case of US and Japanese multinational enterprises. Weltwirtschaftliches Archiv, 136(3), 442–476.
La Croix, S. J., & Liu, M. (2014). A cross-country index of intellectual property rights in pharmaceutical inventions. Research Policy, 44, 206–216.
Lasserre, M. (2007) « Les différentes formes de délocalisations ». https://www.mlasserre.com/educpop/dossierdelocs/lesdifferentesformesdedelocalisations.htm
Lee, J.-Y., & Mansfield, E. (1996). Intellectual property protection and U.S. foreign direct investment. Review of Economics and Statistics, 78(2), 181–186.
LEEM. (2019). Les entreprise du médicament. https://www.leem.org/marche-mondial
Lesser, W. (2000) The effects of TRIPS mandated intellectual property rights on economic activities in developing countries. Cornell University/WIPO. http://www.wipo.org/about-ip/en/index.html?wipo_content_frame=/aboutip/en/studies/index.html
Lesser, W. (2011). Measuring intellectual property ‘strength’ and effects: An assessment of patent scoring systems and causality. The Journal of Business, Entrepreneurship and the Law, 4(2), 345–382.
Lippoldt, D., & Park, W. G. (2003). The impact of trade-related intellectual property rights on trade and foreign direct investment in developing countries. OECD working papers: Special Issue on trade policy, 4(11), 294.
Liu, W. H. (2016). Intellectual property rights, FDI, R&D and economic growth: a cross-country empirical analysis. The World Economy, 39(7), 983–1004.
Mackey, T. K., Lian, B. A., York, P., & Kubic, T. A. (2015). Counterfeit drug penetration into global legitimate medicine supply chains: A global assessment. The American Journal of Tropical Medicine and Hygiene, 92, 59–67.
Maskus, K. E. (1998). The role of intellectual property rights in encouraging foreign direct investment and technology transfer. Duke Journal of Comparative and International Law, 9(1), 109–161.
Maskus, K. E. (2004). Encouraging International Technology Transfer, UNCTAD-ICTSD Project on IPRs and Sustainable Development, Issue Paper No 7.
Maskus, K. E., & Eby-Konan, D. (1994). Trade-related intellectual property rights: Issues and exploratory results. In A. V. Deardorff & R. M. Stern (Eds.), Analytical and negotiation issues in the global trading system. University of Michigan Press.
Nair-Reichert, U. (2000). Patent regimes and the internationalization of economic activities: Some empirical evidence from US multinationals. Georgia Institute of Technology.
Noury, M. (2017). Après les paradis fiscaux, les « paradis » des essais cliniques ? The Conversation. https://theconversation.com/apres-les-paradis-fiscaux-les-paradis-des-essais-cliniques-86375
Park, W. G., & Lippoldt, D. C. (2005). International licensing and the strengthening of intellectual property rights in developing countries during the 1990s. OECD Economic Studies, 2005(1), 7–48.
Pfister, E. (2003). Propriété Intellectuelle et Choix de Localisation. Une Modélisation Théorique. Revue Économique, 54(3), 697–706.
Pfister, E., & Mayer, T. (2001). Investissements Directs et Droits de Propriété Intellectuelles dans les Pays En Voie de Développement. Une Étude Empirique des Choix de Localisation des Multinationales Françaises. Revue Région et Développement, 13, 99–123.
Pratomo, M., & Hastiadi, F. F. (2017). Patent Rights protection system and foreign direct investment (FDI) in developing countries. Advances in Social Science, Education and Humanities Research, 126, 37–42.
Primo-Braga, C. A., & Fink, C. (1998). The relationship between intellectual property rights and foreign direct investment. Duke Journal of Comparative and International Law, 9, 163–188.
Pugatch, N. P. (2006). Measuring the strength of national pharmaceutical intellectual property regimes: Creating a new pharmaceutical IP index. The Journal of World Intellectual Property, 16(4), 373–391.
Rapp, R. T. & Rozek, R. P. (1990). Benefits and costs of intellectual property protection in developing countries. National Economic Research Associations, Inc., Working Paper No. 3.
Robert, J. (2013). « La contrefaçon des produits de santé dans le monde: moyens de lutte et implication du pharmacien d’officine », Thèse de Doctorat Es science pharmaceutiques et ingénierie de la santé, soutenue publiquement le 26 Avril 2013, Universités Angers, France.
Saggi, K. (2000). Trade, Foreign direct investment, and international technology transfer: A survey. World Trade Organization, WT/WGTI/W/88, 19 September 2000.
Samedan Ltd. (2011). International clinical trials. Samedan Pharmaceutical Publisher. http://www.samedanltd.com/magazine/13/issue/162/article/3073
Seyoum, B. (1996). The impact of intellectual property rights on foreign direct investment. Columbia Journal of World Business, 31(1), 50–59.
Smarzynska, B. (2002). Composition of foreign direct investment and protection of intellectual property rights: Evidence from transition economies. World Bank working papers, WP No. 2786, February, 2002.
Smarzynska Javorcik, B. (2004). Does foreign direct investment increase the productivity of domestic firms? In search of spillovers through backward linkages. American Economic Review, 94(3), 605–627.
Smith, P. J. (1999). Are weak patent rights a barrier to U.S. exports? Journal of International Economics, 48, 151–177.
Smith, P. J. (2001). How do foreign patent rights affect U.S. exports, affiliate sales, and licenses? Journal of International Economics, 55, 411–439.
Spigarelli, F., & Wei, H. (2014). The Chinese pharmaceutical market: Driving forces and emerging trends. L’Industria, Rivista di Economia e Politica Industrial, 35(3), 505–530.
Tanaka, H., & Iwaisako, T. (2014). Intellectual property rights and foreign direct investment: A welfare analysis. European Economic Review, 67, 107–124.
Uzunidis, D. (2010). Innovation et Proximité: Entreprises, Entrepreneurs et Milieux Innovateurs. La Revue des Sciences de Gestion, 241, 13–22.
Wang, L. (2013). Intellectual property protection in China. International Information & Library Review, 36(3), 253–261.
WIPO. (2020). Statistiques de propriété intellectuelle dans le monde, différents rapports. http://www.wipo.int/ipstats/fr/
Yacoub, L., & Yacoub, N. (2011) « Quelles politiques d’attractivité ? Les Déterminants de la localisation des investissements directs étrangers pharmaceutiques en Tunisie. ». In Uzunidis D, Laperche B, Boutillier S (Eds) « L’Entreprise dans la Mondialisation. Contexte et Dynamiques d’Investissement et de Développement », 536p, Éditions LeManuscrit, Paris, pp. 405–445.
Yacoub, N. (2007). « Renforcement de la Protection des Brevets, Impact sur les Flux Mondiaux de Commerce et d’Investissements Directs Étrangers. Étude Théorique et Validation Empirique pour L’économie Chinoise », Mémoire de Master de Recherche en Économie, soutenu publiquement le 23 Janvier 2007, Institut Supérieur de Gestion de Sousse.
Yacoub, N. (2012). « Brevetabilité des Médicaments et Innovation Pharmaceutique. Étude Théorique et Validation Empirique pour le cas de la Tunisie », Thèse de Doctorat en Économie de l’innovation, soutenue publiquement le 27 Janvier 2012, Université de Lille Nord de France & Université de Tunis el Manar.
Yacoub, N. (2017). The role of public policies in building up a national pharmaceutical innovation system in Tunisia: Challenges after the Jasmine Revolution. In A. Tsvetkova et al. (Eds.), Innovation in developing and transition countries (pp. 68–85). Edward Elgar Publishing.
Yang, D. (2003). The development of intellectual property in China. World Patent Information, 25, 131–142.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yacoub, N., Souei, H. (2021). Is Drug Patent Protection a Determinant of the Location of Pharmaceutical FDI? China’s Experience. In: Pyka, A., Lee, K. (eds) Innovation, Catch-up and Sustainable Development. Economic Complexity and Evolution. Springer, Cham. https://doi.org/10.1007/978-3-030-84931-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-84931-3_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84930-6
Online ISBN: 978-3-030-84931-3
eBook Packages: Economics and FinanceEconomics and Finance (R0)